MetaCap

IRulya Therapeutics Financial Statements

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRulya Therapeutics revenue and earnings

IRulya Therapeutics reported a net loss of $84.0 million, compared with a loss of $56.8 million a year earlier. Diluted earnings per share came in at -$1.68.

Summary generated from market data by MetaCap's automated system. Methodology

IRulya Therapeutics income statement (annual)

IRulya Therapeutics annual income statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31FY 20182018-12-31
Operating Expenses58.07M57.28M34.62M52.02M90.32M78.89M39.17M12.12M
Research & Development35.38M18.59M9.45M25.18M60.80M61.31M30.21M10.09M
Operating Income-58.07M-57.28M-34.62M-52.02M-90.32M-78.89M-39.17M-12.12M
Interest Expense———————957.00K
Other Income (Expense)486.00K-676.00K-102.00K-997.00K-247.00K00—
Pretax Income-80.77M-56.74M-31.58M-51.94M-89.94M-76.85M-36.98M—
Income Tax3.21M87.00K-197.00K-284.00K0000
Net Income-83.98M-56.83M-31.39M-51.66M-89.94M-76.85M-36.98M-12.48M
Net Income growth (YoY)————————
EPS (Basic)-1.68-1.31-0.84-1.54-3.03-2.63-1.94-3.71
EPS (Diluted)-1.68-1.31-0.84-1.54-3.03-2.63-1.94-3.71
Shares Outstanding (Basic)50.10M43.26M37.24M33.50M29.72M29.18M19.03M3.36M
Shares Outstanding (Diluted)50.10M43.26M37.24M33.50M29.72M29.18M19.03M3.36M
EBITDA-57.93M-57.10M-34.30M-51.81M-89.97M-78.56M-38.98M-12.07M

This table shows 8 annual periods of IRulya Therapeutics's income statement, from FY 2025 back to FY 2018, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a income statement?

More financial data